They found that the death of patients treated with anti-PD-1 and anti-CTLA-4 antibodies was usually caused by colitis [32 (37.0%)] and myocarditis [22 (25.0%)], and the fatal toxic effects usually occurred early after therapy initiation for combination therapy. This evidence concerns the gene PDCD1 and colitis.